Get the Stockscreener App
3.18
4.61%
0.14
Gt Biopharma Inc stock is traded at $3.18, with a volume of 5,613.
It is up +4.61% in the last 24 hours and up +38.26% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$3.04
Open:
$3.1
24h Volume:
5,613
Relative Volume:
0.12
Market Cap:
$6.96M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.4593
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
+17.72%
1M Performance:
+38.26%
6M Performance:
+16.06%
1Y Performance:
+6.71%
1-Day Range:
$3.10
$3.10
1-Week Range:
$2.6216
$3.2799
52-Week Range:
$1.72
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.68 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.15 | 334.49M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.6701 | 103.78M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.18 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
40.91 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
GTBP: GT Biopharma Plans Major Stock Sale | GTBP Stock News - GuruFocus
GT Biopharma registers 120.6M shares for resale by selling stockholders - MSN
GT Biopharma Amends Share Purchase Agreement - TipRanks
GT Biopharma Reports Improved Quarterly Losses - TipRanks
GT Biopharma Expands Convertible Preferred Stock Offering - TipRanks
The Escalator: Zealand Pharma, GT Biopharma, PointClickCare and more - Medical Marketing and Media
This Natural Killer Treatment Could Help Transform How Cancer is Treated - Baystreet.ca
GT Biopharma, Inc. - MENAFN.com
GT Biopharma advances to next trial phase for cancer therapy By Investing.com - Investing.com South Africa
Ellis Martin Report: GT Biopharma Inc's (NASDAQ:GTBP) Michael Breen: Targeting Cancer Cells with a Natural Killer Based Immunotherapy - ABN Newswire
Stocks In Play - Baystreet.ca
Stocks In Play: GT Biopharma, Inc. By Baystreet.ca - Investing.com Canada
GT Biopharma advances to next trial phase for cancer therapy - Investing.com Australia
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - marketscreener.com
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 - GlobeNewswire
GT Biopharma Phase 1 Trial Reveals Early Success: Cancer Drug Shows Safety and Immune Activation - Stock Titan
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - Benzinga
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
TSX Yet to Run out of Steam - The Globe and Mail
GT Biopharma Appoints New Member to its Board of Directors - The Manila Times
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com South Africa
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma Appoints New Member To Its Board Of Directors - marketscreener.com
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Projected to Post Earnings on Wednesday - Defense World
GT Biopharma Board Restructures with New Appointments - TipRanks
GT Biopharma announces private placement deal By Investing.com - Investing.com India
GT Biopharma announces private placement deal - Investing.com
GT Biopharma Secures $5.45M in Private Placement - TipRanks
Nanobodies Market to Reach US$ 2.27 Billion by 2031: Growth - openPR.com
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma (NASDAQ:GTBP) Trading Down 1.7% – Time to Sell? - The AM Reporter
Nanobodies Market Gains Momentum with Advancements in Immunotherapy | Ablynx, Sanofi, Merck - openPR.com
GT Biopharma Appoints Michael Breen as New CEO - TipRanks
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
10.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):